Avacopan is an orally administered therapy for GPA or microscopic polyangiitis (MPA) that blocks the complement C5a receptor (C5aR) and stops the activation of neutrophils, thereby reducing inflammation of blood vessels [6]. This evidence concerns the gene C5AR1 and granulomatosis with polyangiitis.